This reframes the entire comparison: the relevant question is rarely how much weight can a drug take off in a year but how much can be kept off over a decade of continued, tolerable therapy. On that longer horizon, tirzepatide has actual data and retatrutide has, so far, only a promising short-to-medium-term trajectory
Ali, kao to smo ve istakli, u ispitivanju Retatrutida, ukljueno je bilo 338 ljudi sa indeksom telesne mase (BMI) od 30 ili vie, ili sa BMI izmeu 27 i 30, ali sa najmanje jednim oboljenjem povezanim sa telesnom teinom
At TrimRx, we believe that understanding the science behind your treatment is the best way to ensure your safety and success
The choice of a threshold and the decision to dichotomize a continuous scale involve a trade-off between clinical relevance, statistical considerations, and practical feasibility